Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Completes Olympus Dx Buy

NEW YORK (GenomeWeb News) – Beckman Coulter has completed its $780 million acquisition of Olympus' lab-based diagnostics business, the firm announced over the weekend.

Beckman funded the acquisition with $495 million that was raised through the issuance of two, $250 million senior note offerings, and around $240 million from a common stock offering of approximately 4.7 million shares issued to the public at a price of $53 per share.

The Orange County, Calif.-based diagnostics and life science products firm initially announced the deal in February.

"We are confident that the combination of Olympus diagnostics with our business will provide many cross-selling opportunities — the most compelling being promotion of Beckman Coulter's leading immunoassay products to the loyal base of Olympus' chemistry customers," Scott Garrett, Beckman Coulter's chairman, president, and CEO, said in a statement.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.